{"id":306881,"date":"2026-10-14T10:27:28","date_gmt":"2026-10-14T04:57:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=306881"},"modified":"2026-10-14T10:27:28","modified_gmt":"2026-10-14T04:57:28","slug":"fermentation-ingredient-biologics-and-global-generic-stocks-future-edge-watchlist","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/fermentation-ingredient-biologics-and-global-generic-stocks-future-edge-watchlist\/","title":{"rendered":"3 Fermentation Ingredient, Biologics and Global Generic Stocks With a Strong Future Roadmap: Concord Biotech, Shilpa Medicare and Aurobindo Pharma"},"content":{"rendered":"

Concord Biotech Rs 1,369.70, P\/E 51.00. Shilpa Medicare Rs 973.60, P\/E 67.52. Aurobindo Pharma Rs 1,684.60, P\/E 25.46. Closing prices of 13 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Fermentation ingredient, biologics and global generic stocks with the clearest long-term roadmaps today include Concord Biotech in fermentation-based active ingredients, including immunosuppressants and anti-infectives, Shilpa Medicare in active ingredients, formulations, biologics and contract manufacturing and Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets. P\/E stands at 51.00 for Concord Biotech (industry 37.59), 67.52 for Shilpa Medicare (industry 37.59) and 25.46 for Aurobindo Pharma (industry 37.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Fermentation ingredient, biologics and global generic stocks give investors exposure to ingredients, advanced medicines and generics that drug makers and patients rely on. Volumes, export approvals and contract orders decide how much of that demand turns into profit.<\/p>\n

This list covers three fermentation ingredient, biologics and global generic stocks: Concord Biotech for fermentation-based active ingredients, including immunosuppressants and anti-infectives, Shilpa Medicare for active ingredients, formulations, biologics and contract manufacturing and Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n